Clinical trials: SBRT
Breast Cancer
Phase II Multi-center Trial Evaluating 5 Fraction Stereotactic Partial Breast Irradiation Using Gammapod
Stereotactic radiation has been implemented more than 3 decades ago, initially to radiate benign and later malignant tumors within the brain. Doses up to 24 Gy in one session have been used.
- Trial name
- NCT03581136
- Testing
- Dose Fractionation
- Where
- 2 sites in United States
- Volunteers
- 74 people
- Sponsor
- University of Texas Southwestern Medical Center
Renal Tumor
SABR for Renal Tumors
Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. The usual treatment for this type of cancer is surgery. Considering the most common patients are an average age of 65 and some are not suitable candiates for…
- Trial name
- NCT03747133
- Testing
- Stereotactic Ablative Radiotherapy
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- University Health Network, Toronto
Metastatic Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer
Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect
The purpose of this study is to determine efficacy, safety of Stereotactic Body Radiotherapy (SBRT) in combination with immunotherapy in participants with metastatic non-small cell lung cancer (NSCLC) who are eligible for an…
- Trial name
- I-SABR (NCT03825510)
- Testing
- Stereotactic Body Radiotherapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Crozer-Keystone Health System
Hepatocellular Carcinoma
Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma
Trans-arterial chemoembolization (TACE) is a standard treatment for patients with hepatocellular carcinoma (also called liver cancer). This is where chemotherapy is injected into the arteries of the liver and liver cancer.
- Trial name
- TACE (NCT03895359)
- Testing
- Stereotactic Body Radiation, Transarterial Chemoembolization
- Where
- Canada
- Volunteers
- 128 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Prostatic Neoplasms
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist (LHRHa) delays metastatic progression as assessed by prostate specific membrane…
- Trial name
- PRIMORDIUM (NCT04557059)
- Testing
- Radiotherapy, LHRHa, Apalutamide
- Where
- 141 sites in United States, Australia and 19 more
- Volunteers
- 691 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Hepatocellular Carcinoma
TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients
This trial is designed to be the initial prospective pilot investigation of the effectiveness of combined SBRT and TACE as bridging therapy for HCC patients awaiting liver transplanation.
- Trial name
- NCT01918683
- Testing
- TACE transarterial chemoembolization, stereotatic body radiotherapy (SBRT)
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Early Lung Cancer, Stereotactic Body Radiotherapy
Single Ultra-high Dose Stereotactic Body Radiation Therapy for Early Lung Cancer
The goal of this prospective single-arm phase II study is to study the efficacy and safety of stereotactic body radiotherapy (SBRT) for early lung cancer.
- Trial name
- USBRT-1 (NCT05802654)
- Testing
- SBRT
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University Third Hospital
Cutaneous, Head and Neck Cancer Squamous Cell Carcinoma
Stereotactic Post-operative Radiotherapy for Intraparotid Metastatic Cutaneous Squamous Cell Carcinoma
The purpose of this study is to compare the effectiveness and side effects of stereotactic radiotherapy (5 sessions) against conventional (standard) radiotherapy (20-30 sessions) for the treatment of skin cancer involving the…
- Trial name
- SPRINT (NCT07337161)
- Testing
- SBRT, Standard Radiation
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- David Palma
Brain Metastases, Chemotherapy
HFSRT With Concurrent TMZ for Large BMs
A multi-center randomized phase III trial was conducted to investigate the feasibility and safety of adding temozolomide to hypofractionated stereotactic radiotherapy for large brain metastases.
- Conditions
- Brain Metastases, Chemotherapy, Radiotherapy
- Trial name
- NCT03778541
- Testing
- Temozolomide, hypofractionated radiotherapy
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Chinese Academy of Medical Sciences
Stage I Non-Small Cell Lung Cancer
Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
This phase I trial studies the side effects and best dose of atezolizumab that can be given together with stereotactic body radiation therapy (SBRT) in treating patients with stage I non-small cell lung cancer that cannot be…
- Trial name
- NCT02599454
- Testing
- Atezolizumab, Stereotactic Body Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Megan Daly, MD
Non-small Cell Lung Cancer
Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer
Radiation can induce immunogenic cell death, local release of inflammatory cytokines, and damage associated molecular patterns (DAMPs) resulting in local effects on endothelial cell expression of adhesion receptors, increased…
- Trial name
- SKYROCKET (NCT05034055)
- Testing
- atezolizumab / tiragolumab
- Where
- South Korea
- Volunteers
- 45 people
- Sponsor
- Yonsei University
Recurrent Glioma, High-grade Meningioma
Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors
This is an open label phase I clinical trial with two arms, representing single and fractionated radiation therapy (Figure 4.1). Within each arm the radiation dose is pre-determined and not escalated.
- Conditions
- Recurrent Glioma, High-grade Meningioma, Brain Metastasis
- Trial name
- NCT01324635
- Testing
- Panobinostat, Stereotactic body radiation therapy, Quality-of-life assessment
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Borderline Resectable Pancreatic Adenocarcinoma
Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma
The purpose of this study is to characterize the safety, preliminary efficacy, and immune biologic activity of CAN-2409 + prodrug (valacyclovir or acyclovir) in subjects with borderline resectable pancreatic cancer who are being…
- Trial name
- PaTK02 (NCT02446093)
- Testing
- Aglatimagene besadenovec, Chemoradiation, Stereotactic body radiation therapy
- Where
- 3 sites in United States, Mexico
- Volunteers
- 54 people
- Sponsor
- Candel Therapeutics, Inc.
Lung Cancer
Metformin in Non Small Cell Lung Cancer (NSCLC)
The goal of this clinical research study is to learn if giving metformin in combination with radiation therapy is more effective than radiation therapy alone.
- Trial name
- NCT02285855
- Testing
- Metformin, Stereotactic body Radiotherapy (SBRT)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
Small-cell Lung Cancer
A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer
This study is for subjects with untreated Stage IV small cell lung cancer. Subjects will be given radiation therapy for five days, followed by standard of care chemo-immunotherapy (etoposide + carboplatin or cisplatin +…
- Trial name
- NCT04951115
- Testing
- Carboplatin, Cisplatin, Etoposide
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer Metastatic
Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer
The purpose of this study is to compare the effects of ablative therapy (radiation or surgery) to all sites of disease combined with standard treatments on prostate cancer, compared to the standard or usual treatments used to…
- Trial name
- PLATON (NCT03784755)
- Testing
- Ablative Radiation Therapy, Standard of care
- Where
- 18 sites in Canada
- Volunteers
- 409 people
- Sponsor
- Canadian Cancer Trials Group
Hepatocellular Carcinoma
SBRT Versus Ablation for Perivascular Hepatocellular Carcinoma
This trial is a multi-center, phase III, randomized (1:1) clinical trial. The aim is to explore the efficacy and safety of SBRT for perivascular hepatocellular carcinoma, compared with RFA.
- Trial name
- SAIL (NCT04434989)
- Testing
- Stereotactic Body Radiation Therapy, radiofrequency ablation
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Sun Yat-sen University
Spine Metastasis
A Phase II Trial Evaluating Radiation Boost to Painful Spinal Metastases
Spine SBRT is considered a standard of care for the treatment of spinal metastases. Compared to conventional radiation therapy, spine SBRT delivers high doses of radiation to the affected areas to the spinal metastases.
- Trial name
- OPTIMAL (NCT07478289)
- Testing
- Radiation Boost
- Where
- Canada
- Volunteers
- 108 people
- Sponsor
- Sunnybrook Health Sciences Centre
Pancreatic Cancer
SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer
This is a Phase II, prospective, single-arm exploratory clinical trial designed to evaluate the efficacy and safety of stereotactic body radiotherapy followed by ipilimumab N01 plus sintilimab in combination with nab-paclitaxel…
- Trial name
- NCT07683221
- Testing
- SBRT + Ipilimumab N01 + Sintilimab + AG Chemotherapy
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Shandong Cancer Hospital and Institute
Recurrent Oligometastatic Disease
Radiosurgery for Patients Recurrent Oligometastatic Disease
This study will evaluate the feasibility of radiosurgery for all metastatic sites in patients presenting with oligometastatic disease, defined here as 5 or fewer sites of metastatic disease involving 3 or fewer organ systems.
- Trial name
- NCT01345552
- Testing
- Stereotactic Radiosurgery (SRS)
- Where
- United States
- Volunteers
- 173 people
- Sponsor
- Steven Burton